Top Markets
Coin of the day
Elicio Therapeutics, Inc. Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

ELTX
주식 순위 #24646
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to... Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfolio also encompasses ELI-004, an AMP-modified CpG adjuvant that forms part of ELI-002; ELI-007, a lymph node-targeted AMP-peptide vaccine addressing mutant BRAF-driven cancers; and ELI-008, a multivalent lymph node-targeted AMP-peptide vaccine for cancers expressing mutant TP53. Furthermore, Elicio is advancing ELI-005, a vaccine candidate for preventing COVID-19, and ELI-011 for hematological malignancies. Another program, ELI-012, is an mKRAS TCR T cell AMP-lifier designed for combined use with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company's operations are headquartered in Boston, Massachusetts.
주가
$3.05
시가총액
$58.15M
변동 (1일)
-0.81%
변동 (1년)
-73.32%
국가
US
거래 Elicio Therapeutics, Inc. (ELTX)

카테고리

Elicio Therapeutics, Inc. (ELTX)의 배당 수익률 기록
Elicio Therapeutics, Inc. (주식 심볼: ELTX)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Elicio Therapeutics, Inc. (ELTX)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)
회사 배당 수익률 국가
0.00%
US
0.00%
NL
3.12%
AU
0.00%
US
0.00%
CH